Subject
Pharmaceutical Science,Pharmacology
Reference66 articles.
1. ARIAD Pharmaceuticals Inc., 2017. ALUNBRIGTM (brigatinib): US prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208772lbl.pdf (accessed 14.02.18).
2. Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non–small cell lung cancer (NSCLC);Camidge;J. Clin. Oncol.,2015
3. Acquired resistance to TKIs in solid tumours: learning from lung cancer;Camidge;Nat. Rev.Clin. Oncol.,2014
4. Brigatinib in crizotinib-refractory ALK+ NSCLC: Central assessment and updates from ALTA, a pivotal randomized phase 2 trial;Camidge;J. Thorac. Oncol.,2017
5. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future;Chan;Transl. Lung Cancer Res.,2015
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献